A retrospective multicenter study assessing the effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stage
Latest Information Update: 15 Feb 2022
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
Most Recent Events
- 15 Feb 2022 New trial record
- 15 Jan 2022 Results published in the Journal of the Neurological Sciences